1	Title: MicroRNAs in adipocyte-derived extracellular vesicles in maternal and cord blood
2	are related to neonatal adiposity
3	
4	Authors
5	Pooja Kunte ¹ *, Matthew Barberio ² *, Pradeep Tiwari ¹ , Krishna Sukla ¹ , Brennan Harmon ³ ,
6	Samuel Epstein ³ , Dattatray Bhat ¹ , Kayla Authelet ³ , Madeleine Goldberg ³ , Sudha Rao ⁴ ,
7	Hemant Damle ⁵ , Robert J Freishtat ³ , Chittaranjan Yajnik ¹ (corresponding)
8	
9	*Co-first authors
10	
11	Affiliations
12	¹ Diabetes Unit, KEM Hospital Research Centre, Pune, India
13	² Department of Exercise and Nutrition Sciences, The Milken Institute School of Public
14	Health, George Washington University, Washington, D.C.
15	³ Center for Genetic Medicine Research, Children's National Hospital, Washington, D.C.
16	⁴ Genotypic Technology Pvt. Ltd., Bangalore, India
17	⁵ S K Navle hospital, Pune, India.
18	
19	
20	Corresponding Author(s)
21	<u>csyajnik@gmail.com</u>
22	rfreishtat@childrensnational.org
23	
24	
25	Keywords: Adipocyte-derived extracellular vesicles (ADsEV), microRNA, maternal and cord

blood, neonatal adiposity 26

All rights reserved. No reuse allowed without permission.

1 Abstract

- 2 Background: Maternal body size, nutrition, and hyperglycemia contribute to neonatal body
- 3 size and composition. There is little information on maternal-fetal transmission of messages
- 4 which influence fetal growth. We analyzed adipocyte-derived small extracellular vesicular
- 5 (ADsEV) microRNAs in maternal and cord blood to explore their adipogenic potential.
- 6 **Methods:** We studied 127 mother-neonate pairs (51 lean and 76 adipose neonates, in 68
- 7 NGT and 59 GDM pregnancies). Adiposity refers to highest tertile (T3) of sum of skinfolds in
- 8 neonates of normal glucose tolerant (NGT) mothers, lean to lowest tertile (T1). ADsEV
- 9 miRNAs from maternal and cord blood samples were profiled on Agilent 8*60K microarray.
- 10 Differential expression (DE) of ADsEV miRNAs in adipose vs. lean neonates was studied
- 11 before and after adjustment for maternal gestational diabetes mellitus (GDM), adiposity,
- 12 and vitamin B12-folate status. **Results:** Multiple miRNAs were common in maternal and cord
- 13 blood and positively correlated. We identified 24 maternal and 5 cord blood miRNAs
- 14 differentially expressed (p≤0.1) in the adipose neonate group, and 19 and 26 respectively, in
- 15 the adjusted analyses. Even though DE miRNAs were different in maternal and cord blood,
- 16 they targeted similar adipogenic pathways (e.g., the forkhead box O (FOXO) family of
- 17 transcription factors, mitogen-activated protein kinase (MAPK) pathway, transforming
- 18 growth factor beta (TGF-β) pathway). Maternal GDM and adiposity were associated with
- 19 many DE ADsEV miRNAs.
- 20 **Conclusion:** Our results suggest that the DE ADsEV miRNAs in mothers of adipose neonates
- are potential regulators of fetal adiposity. Further, the composition and functionality of
- 22 miRNAs may be influenced by maternal hyperglycemia, adiposity, and micronutrient status
- 23 during pregnancy.
- 24
- 25
- 26

27 Abbreviations

- 28 PMNS Pune Maternal Nutrition Study
- 29 PCS Pune Children Study
- 30 SSF Sum of skin folds
- 31 EV Extracellular vesicles
- 32 ADsEV Adipocyte derived small extracellular vesicles
- 33 GDM Gestational diabetes mellitus
- 34 NGT Normal glucose tolerant
- 35 FABP4 Fatty acid binding protein 4
- 36 DE miRNA Differentially expressed microRNA
- 37

Introduction 1

2 Women undergo many physiological adaptations during the gestational period to promote healthy fetal growth¹. The developing fetus depends on transfer of nutrients from 3 4 the mother for the growth of its developing tissues and organs. Exposure of the fetus to 5 overnutrition (maternal hyperglycemia) or undernutrition (maternal macro- and micronutrient deficiencies) during the intra-uterine development could create a 'memory' of 6 7 malnourishment which is proposed to "program" its risk for future adiposity, diabetes, and 8 cardiovascular diseases². This is the science of the Developmental Origins of Health and 9 Disease (DOHaD)³.

The Pune birth cohort studies (Pune Children's Study (PCS) and Pune Maternal 10 11 Nutrition Study (PMNS)) provided significant insight into the fetal origins of elevated risk for 12 chronic disease⁴. The PMNS described the unique 'thin-fat' Indian baby which has lower 13 birth weight and lean mass, but comparable fat mass, to a European baby⁵. The thin-fat 14 Indian baby also has higher leptin and insulin but lower adiponectin concentrations in the 15 cord blood⁶. This neonatal 'thin-fat' phenotype is thought to originate in multi-generational 16 maternal undernutrition and is aggravated by maternal glycemia⁷. This phenotype continues 17 into postnatal life and contributes to the higher cardiometabolic risk in Indians compared to 18 Europeans⁸. In the Pune studies, low birth weight was associated with childhood insulin 19 resistance, and a maternal imbalance of low vitamin B12 and high folate status was associated with high adiposity and insulin resistance in the offspring^{9,10}. Prediabetes in 18-20 21 year-old offspring was predicted by poor linear growth in utero and by high normal glycemia 22 in the mother during pregnancy.

23 Understanding the molecular pathways leading to fetal adiposity are of interest to 24 the 'primordial' prevention of diabetes and other cardiometabolic diseases. Several 25 mechanisms, such as genetics, epigenetics, nutrients, and pro-inflammatory cytokines are potential drivers of this intergenerational influence¹¹. Individually, they may explain only a 26 27 small proportion of the effect. For instance, genetic markers from genome wide association 28 studies account for less than 15% of the overall observed variance in the obesity 29 phenotypes^{12,13}. More recently small extracellular vesicles (sEV), sometimes called 30 exosomes, came into focus as potential mediators of intergenerational transfer due to their 31 ability to cross the placenta, the rise in sEV number in the maternal circulation during 32 pregnancy and their important role in cell-to-cell communication ^{14,15}.

33 sEVs are endocytic vesicles with a lipid bilayer, are released by a wide range of cell 34 types and can transfer molecular cargo (e.g., proteins, nucleic acids, lipids) from the original 35 secreting cell to a recipient cell in a paracrine or endocrine fashion¹⁶. More specifically, adipocyte-derived sEVs (ADsEV) have been shown to be a major source of circulating 36 37 microRNAs (miRNAs) which can regulate gene expression in distant tissues^{17,18}. We have 38 previously demonstrated that ADsEV miRNA contents are altered by obesity and normalized following significant weight-loss (i.e., from bariatric surgery)^{19,20,21}. Further, ADsEVs from 39 individuals with obesity alter macrophage cholesterol efflux and gene expression in vitro²². 40 Given the important role of ADsEVs in obesity-related co-morbidities^{23,24}, our objective was 41

medRxiv preprint doi: https://doi.org/10.1101/2022.10.30.22281708; this version posted November 1, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

to explore ADsEV miRNAs as potential mediators of maternal-to-fetus communication and 1

2 transfer of intergenerational risk for adiposity. In this analysis, we examined differences in

3 miRNA profiles of ADsEVs isolated from maternal and cord blood plasma samples collected

4 at delivery in pregnancies with adipose and lean neonates, with the hypothesis that ADsEV

5 miRNAs will enhance adipogenic pathways.

6

7 Methods

8 **Cohort description**: The 'Intergenerational programming of diabesity in offspring of 9 women with gestational diabetes mellitus' (InDiaGDM) study investigated the impact of 10 maternal hyperglycemia on the risk of diabesity (diabetes + adiposity) in the offspring and 11 the modifying influence of vitamin B12 and folate status²⁵. Details of inclusion and exclusion 12 criteria are shown in the flowchart (Supplementary figure 1). All participating women signed 13 an informed consent, and the study was approved by the institutional ethics committee 14 (KEM EC no. 1404, SKNMC /Ethics/App/2014/265).

15 Maternal and Neonatal Data. Maternal socio-demographic data, medical and 16 obstetric information, and standard anthropometric measurements were taken at 28 weeks

17 gestation. A fasting oral glucose tolerance test (OGTT, 75-gram anhydrous glucose,

18 IADPSG²⁶) was performed at that time. Those diagnosed with gestational diabetes mellitus

19 (GDM) were appropriately advised. Delivery details (gestational age and type of delivery

20 (e.g., vaginal, cesarean)) were recorded. Detailed neonatal anthropometry was performed

21 within 24 hours of delivery (i.e., weight, length, head, and abdominal circumferences,

22 triceps, and subscapular skin folds).

23 Biospecimen collection and determination of blood metabolites: The following 24 measurements were made on maternal and cord blood: hemogram (complete blood count), 25 plasma glucose, insulin, total and HDL cholesterol, triglycerides, total vitamin B12, total 26 homocysteine and folate. Supplementary table 1 describes laboratory methods used for 27 these measurements.

28 Definitions: Neonatal adiposity (sex-stratified) was defined as highest tertile (T3) of 29 sum of skinfolds (SSF) of neonates born to normal glucose tolerant (NGT) mothers. T1 were 30 classified as lean. Maternal adiposity was defined from sub-scapular skin folds at 28 weeks' 31 gestation: above median (adipose) and below median (lean). GDM was diagnosed using 32 IADPSG criteria²⁶. Maternal vitamin B12 and folate status were classified as adequate if 33 above and inadequate if below the median concentration for the cohort.

34 Sample processing randomization and blinding: To avoid unintentional sampling 35 bias, the sample IDs were randomly ordered five times and then mother-neonate pairs were grouped into batches of eight pairs (N=16). Laboratory staff were provided with a blinded 36 37 (i.e., no group information or metadata) processing order for samples.

38 ADsEV isolation: Maternal and cord blood plasma samples at delivery were treated with 10µL [611U/mL] Thrombin (System Biosciences, Palo Alto, CA, USA) per 0.5mL plasma. 39 After a 10-minute incubation at room temperature, and centrifugation in a standard 40

41 microcentrifuge at 12,298 g for 10 minutes, the supernatant was removed and filtered

- 1 through a 0.2µm cellulose acetate syringe filter (VWR International, Radnor, PA, USA). Total
- 2 EVs were isolated from filtered plasma supernatants using ExoQuick exosome precipitation
- 3 solution (System Biosciences, Palo Alto, CA, USA) according to manufacturer's instructions.
- ADsEVs were positively selected with a fatty acid-binding protein antibody (FABP4) (0.5 4
- 5 mg/mL; Mouse IgG monoclonal antibody, Abgent cat. No AM2235b, Inc., San Diego, CA,
- USA) using a magnetic capture technique (EasySep[™] "Do-It-Yourself" Positive Selection Kit II 6
- 7 - StemCell Technologies, Vancouver, BC, Canada). After positive selection, the ADsEVs were
- 8 resuspended in TRIzol[™] Reagent (ThermoFisher Scientific, Waltham, MA, USA).
- 9 MicroRNA isolation and assessment: Exosomal RNA isolation was completed using 10 TRIzol reagent (ThermoFisher Scientific, Waltham, MA USA) according to manufacturer's 11 instructions. The quantity and quality of the RNA were assessed using a Nanodrop 2000
- 12 (ThermoFisher Scientific, Waltham, MA USA) and Bioanalyzer 2100 (Agilent Technologies,
- 13 Santa Clara, CA USA). Samples with OD260/OD280 ratio >1.5 and <2.2 were selected for
- 14 miRNA profiling. The miRNA labeling was performed using miRNA Complete Labeling and
- 15 Hyb Kit (Agilent Technologies, Santa Clara, CA, USA) with a sample input of 10uL of total
- 16 RNA. Samples were hybridized to Agilent Human miRNA Microarray, Release 21.0, 8x60K.
- 17 The microarray slides were scanned using an Agilent scanner (G2600D) and raw data
- 18 extracted using Agilent Feature Extraction software (Version 11.5.1.1).
- 19 Statistical analyses: Sample size and power calculations were done using "ssize" 20 package in R to measure a reliable fold change of 2.0 in miRNA expression in the adipose group with respect to lean at a significance level of 0.05. A total of 120 individuals (~60 in 21 22 each group) would provide a power of 80%.
- 23 **Demographic characteristics:** Normally distributed data are presented as mean (SD) and skewed data as median (25th and 75th percentiles). The significance of differences 24 25 between groups was tested by Student's t test (if normally distributed) or Mann-Whitney 26 test (if skewed).
- 27 MicroRNA data: Raw microRNA expression data was log2 transformed and 28 normalized using the 90th Percentile shift normalization method in GeneSpring GX (Version 29 14.5) software. MiRNAs that showed true signal in at least 10% of samples were selected for 30 further analysis. To check if the average expression of all ADsEV miRNAs was upregulated or 31 downregulated in the adipose group, mean z-scores of miRNA expression values were 32 calculated for all miRNAs from lean and adipose groups in maternal plasma and cord blood 33 and the distribution of z-scores between the groups were compared. We also investigated if 34 the ADsEV miRNA expression in maternal plasma samples correlated with those from cord 35 blood samples by applying a Spearman correlation test. The central objective of the study was to compare differential expression of ADsEV 36 37 miRNAs in maternal plasma and cord blood of adipose (T3) and lean neonates (T1).
- 38 Differential expression of miRNAs between groups was calculated by Student's T test for
- 39 those normally distributed and by Mann-Whitney test for skewed. Fold changes were
- 40 calculated by formula: FC = average (miRNA expression in adipose – median expression of
- 41 miRNA in lean). This was done in 2 steps: 1. Without adjusting for confounding variables and

2. with adjusting for confounding variables (maternal GDM status, adiposity, and maternal 1 2 vitamin B12 and folate status for maternal samples, and additionally neonatal gender for cord blood samples) by multiple linear regression analysis. We used a discovery significance 3 4 of $p \le 0.1$ and a FC $\ge |1.2|$ and represented it as a volcano plot generated using ggplot 2^{25} 5 package in R. Functional analyses: Differentially expressed miRNAs with p-value≤0.1 were selected 6 7 for miRNA target gene and functional enrichment using Mienturnet²⁷ software 8 (http://userver.bio.uniroma1.it/apps/mienturnet/; March 2019). Target enrichment was 9 done using miRTarBase 8.0 and the functional enrichment was conducted by using the KEGG 10 database. This tool computationally maps the given list of miRNAs to their target 11 genes/proteins in their reference database (KEGG/miRTarBase) and fetches a list of target 12 genes that are computationally predicted and/or experimentally confirmed. Relevant 13 overrepresented classes of annotated genes with at least 1 miRNA-target interaction were 14 selected for functional enrichment and are studied. MicroRNAs targeting biological 15 pathways belonging to the following KEGG pathway categories are not shown because they 16 are of no direct interest in this analysis: cancer, bacterial/viral/parasitic infectious diseases, 17 excretory, immune and nervous system, immune and neurodegenerative diseases, 18 environmental adaptation, aging, substance abuse, and drug resistance. Pathways with FDR 19 p-value≤0.05 and related to adipogenesis, adipocyte differentiation and adipocyte signaling 20 were considered relevant from the KEGG pathway categories like cell growth and 21 development, signal transduction, metabolism, endocrine and cardiovascular health, 22 digestive systems and studied in detail. Fold changes of each DE miRNA in adipose group are 23 shown in a barplot. MiRNAs and their targeted genes are represented as a network plot, generated using ggnet²⁸ package in R. A bubble plot of the functionally enriched miRNAs 24 25 was generated using ggplot2²⁹, where colour and size of each bubble stands for its FDR p-26 value and the number of targeted genes, respectively. Adipogenesis related pathways 27 targeted by both maternal and cord blood DE miRNAs are highlighted using a Sankey diagram generated using SankeyMatic³⁰ software. 28 29 Differential expression of miRNAs in relation to maternal conditions 30 (hyperglycemia and adiposity during pregnancy): To check the influence of maternal 31 conditions (i.e., hyperglycemia and adiposity during pregnancy) on ADsEV miRNA profile, 32 differential expression analysis was carried out in both maternal and cord blood ADsEV 33 miRNA profiles between following groups: 1. GDM and NGT (unadjusted and adjusted for confounders: maternal adiposity, B12 and folate status) and 2. maternal adiposity (below 34 35 and above median) (unadjusted and adjusted for confounders: GDM, B12 and folate status). The lists of DE miRNAs from the unadjusted and adjusted analyses were combined and 36 duplicates were removed. DE miRNAs from both analyses were subjected to functional 37 38 enrichment in Mienturnet and adipogenesis related pathways were screened. A Venn 39 diagram was made using jvenn³¹ software to compare the adipogenesis related microRNAs 40 from the three analyses: 1. Neonatal adiposity, 2. Maternal GDM, and 3. Maternal adiposity 41 in both maternal and cord blood.

- 1
- 2

3 Results

4 The InDiaGDM study enrolled 413 women after applying inclusion and exclusion 5 criteria. Of these, 330 women delivered at study centers. Two hundred and seventy-nine 6 mother-neonate pairs had the necessary data and matching maternal plasma and cord 7 blood samples. From these, guided by a power calculation, we randomly selected 127 8 mother-neonate pairs, including 51 lean and 76 adipose neonates, for ADsEV miRNA 9 analyses (supplementary figure 1). There were no significant differences between the 10 included (N=127) and excluded (N=152) mothers with respect to age, parity, weight, and 11 BMI, or in their neonates with respect to gender, gestational age at the time of birth, and 12 birth weight (supplementary table 2).

13 Characteristics of mothers and neonates: Mothers were a median (IQR) age of 27 (5) years old, 155 (7) cm tall, and had a BMI of 27.1 (6.6) kg/m² at 28 weeks' gestation. 14 15 Of the 127 mothers, 68 were NGT and 59 were diagnosed with GDM. The mothers of 16 adipose neonates had higher weight, BMI, SSF, and fasting glucose compared to mothers of 17 lean neonates but similar levels of total and HDL cholesterol, triglycerides, vitamin B12, and 18 folate (Table 1A). Adipose neonates had higher birth weight, length, SSF, and placental 19 weight compared to lean neonates (Table 1B). Mothers of adipose neonates had higher 20 prevalence of adiposity and GDM.

- 21
- 22

Differential expression of ADsEV miRNAs in maternal plasma and cord blood:

23 Of the 2549 miRNAs profiled in the Agilent 8*60k microarray, 742 miRNAs were 24 detected in at least 1 sample. We chose miRNAs which were expressed in at least 10% of 25 samples for further analysis (139 miRNAs in maternal and 144 in cord blood)

26 (supplementary figure 2). We found that 118 miRNAs were common in maternal and cord

27 blood. Of these, 74 (63%) were positively and significantly correlated ($p \le 0.05$).

28

29 Comparison between the adipose and lean neonate groups identified 24 miRNAs 30 differentially expressed in their mothers at $p \le 0.1$ (13 with FC ≥ 1.25 and 1 with FC ≤ -1.25). 31 After adjusting for maternal GDM, adiposity, vitamin B12, and folate status, 19 miRNAs 32 remained differentially expressed between the groups (5 with FC≥1.25 and 1 with FC≤-1.25) 33 (Table 3A, Figure 1). In the cord blood, 5 ADsEV miRNAs were differentially expressed (3 34 with $FC \ge 1.25$ in adipose group). After adjusting for neonatal sex, maternal GDM, adiposity, 35 vitamin B12, and folate status, the number of DE miRNAs in the cord blood increased to 26 (16 with FC≥1.25 and 3 with FC≤-1.25 in adipose group) (Table 3B, Figure 1). After combining 36 37 the lists of DE miRNAs in unadjusted and adjusted analyses and removing duplicates, 39 38 miRNAs in maternal and 29 miRNAs in cord blood were found to be differentially expressed 39 in adipose group. 40 We investigated biological functional profile of the differentially expressed miRNAs.

41 Target enrichment analysis (Mienturnet) highlighted 11 miRNAs to be upregulated in plasma

of mothers of adipose neonates compared to those of lean neonates (7 miRNAs in 1 2 unadjusted analysis: hsa-miR-1202, hsa-miR-1234-3p, hsa-miR-212-3p, hsa-miR-33b-3p, hsamiR-451a, hsa-miR-4271 and hsa-miR-5787; and 4 miRNAs in the adjusted analyses: hsa-3 miR-211-3p, hsa-miR-212-3p, hsa-miR-483-3p, hsa-miR-4649-3p). The fold changes are 4 5 shown in Table 2 and Figures 2 and 3. Further screening based on KEGG ontology revealed 4 6 miRNAs to be targeting genes involved in pathways related to adipogenesis. 7 Target enrichment analysis in the cord blood highlighted 11 miRNAs (4 miRNAs in 8 unadjusted analysis, two upregulated: hsa-miR-483-5p, hsa-miR-3162-3p, two 9 downregulated: hsa-miR-15a-3p, hsa-miR-342-3p; and 7 miRNAs in the adjusted analysis 10 five upregulated: hsa-miR-1225-5p, hsa-miR-181b-5p, hsa-miR-204-5p, hsa-miR-3162-3p, 11 hsa-miR-519e-3p; and two downregulated: hsa-miR-92a-3p, hsa-miR-212-3p). Based on 12 KEGG ontology, 9 miRNAs of these were targeting genes involved in pathways related to 13 adipogenesis. 14 We used a Sankey diagram (figure 4) to depict the inter-relationships between 15 differentially expressed miRNAs in maternal and cord blood (of adipose neonates) and their 16 targeted adipogenic pathways. The highlighted pathways included adipocytokine signaling, 17 FoxO signaling, MAPK signaling, Hedgehog signaling, Wnt signaling, insulin signaling, AGE-18 RAGE signaling, cAMP signaling, JAK-STAT signaling, Ras signaling, and TGF-beta signaling. 19 We compared differential expression of ADsEV miRNAs in plasma of adipose vs. non-20 adipose and in GDM vs NGT mothers and in the cord blood of their neonates. We found 127 21 DE ADsEV miRNAs in adipose and 106 in GDM mothers, and 57 and 82 in the cord blood, 22 respectively. Of these, 25 miRNAs in the adipose and 19 in the GDM mothers were related 23 to adipogenesis, the corresponding number in the cord blood was 16 and 17 respectively. 24 Figure 5 shows that 28 miRNAs were common in maternal blood amongst adipose 25 mothers, GDM mothers and adipose neonates and 3 of them were related to adipogenesis: 26 hsa-miR-451a, hsa-miR-212-3p, hsa-miR-1234-3p and 13 miRNAs were common in cord 27 blood of which only 1 hsa-miR-204-5p was related to adipogenesis based on KEGG ontology. 28 29

30

31 Discussion

32 There are few reports of ADsEV miRNAs in mother-neonate pairs. We investigated 33 the association between ADsEV miRNAs in maternal and cord blood with neonatal body 34 composition to understand their potential influence on neonatal adiposity. A large majority 35 (~85%) of ADsEV miRNAs in maternal and cord blood were common, and two-thirds of these 36 were positively correlated suggesting a crosstalk between maternal adipose and neonatal 37 tissue. Maternal adiposity and hyperglycemia, two major determinants of neonatal 38 adiposity were both associated with differential expression of a relatively large number of 39 ADsEV miRNAs in maternal and fetal circulation, a fifth of these were functionally related to 40 adipogenesis. In the maternal circuit, these may represent adipose tissue dysfunction (i.e., 41 adiposopathy) and have the potential to influence fetal growth and body composition.

Our primary analysis was to investigate maternal and cord blood miRNAs associated 1 2 with neonatal adiposity. The tables 2 and 3 and the Sankey figure (Figure 4) show that the differentially expressed miRNAs were different in maternal and cord blood (except hsa-miR-3 4 212-3p which was common). Interestingly, they targeted the genes well-known to influence 5 cellular signaling pathways related to adipogenesis. (FoxO, MAPK, Insulin, AGE-RAGE signaling, etc.) (figure 4). Literature survey revealed experimental evidence of the 6 7 involvement of some of these miRNAs in aspects of adipogenesis. Maternal miRNAs hsa-8 miR-483-3p (FC= 3.99 in adipose group) and hsa-miR-212-3p (FC=0.282 in adipose group) 9 have been associated with lipid accumulation and adipocyte differentiation in low-birthweight adult humans³², and with increased subcutaneous adipose tissue inflammation³³, 10 11 respectively. In an earlier study we found that hsa-miR-212-3p is associated with increased risk of glucose intolerance in young adult PMNS female participants³⁴. Fetal miRNAs hsa-12 13 miR-204-3p (FC=9.87 in adipose group) and hsa-miR-342-3p (FC=-0.098) have been shown to promote adipogenic differentiation of mesenchymal stem cells^{35,36} and hsa-miR-15a (FC= 14 -0.912) to regulate intramuscular adipogenesis³⁷. Given that neonates have a substantial 15 proportion of brown adipose tissue (BAT) and that Indians have lower BAT compared to 16 17 Europeans, we investigated if any of these DE miRNAs have originated in the BAT. 18 Intriguingly, hsa-miR-92a-3p (FC= -0.36) and hsa-miR-181 (FC= 0.71 in adipose group) which are associated with brown fat activity^{38,39} are found to be differentially expressed only in 19 cord blood, reflecting active brown fat activity in neonates. Together our results show a role 20 21 for DE miRNAs in influencing maternal adipocyte function and fetal adipogenesis. We 22 consider that our results provide an insight in the possible role of ADsEV miRNAs (maternal 23 and fetal) in influencing neonatal adiposity and raise the possibility that they could act as 24 maternal-fetal signaling system. 25 Growth and development of the fetus depends on coordinated timely expression of genes which is epigenetically regulated⁴⁰. Body composition of the fetus is probably 26 27 determined from very early pregnancy when the fate of the three germ layers is decided 28 (gastrulation). Adipogenesis involves 'commitment' of mesenchymal stem cells to develop 29 as pre-adipocytes which subsequently differentiate into adipocytes⁴¹. Several specific genes 30 regulate these steps and the expression of these genes in turn is regulated by DNA methylation, histone modifications and specific miRNAs^{42,43,44}. The role of DNA methylation 31 in adipogenesis has been studied^{45,46} but there is little information on the other epigenetic 32

33 mechanisms (i.e., miRNA regulation). Light microscopic studies in human abortuses

- 34 demonstrate that pre-adipocyte to adipocyte differentiation happens between 19 to 23
- 35 weeks, after which period only adipocyte size increases by lipid accumulation⁷. Two major
- maternal determinants of these processes are maternal nutrition (both macro- and micro-36
- 37 nutrients) and her metabolism (diabetes and associated metabolic abnormalities)⁴⁷. There is
- 38 only scant information on how these two stimuli influence molecular adipogenesis in the
- 39 baby, though insulin secretion by fetal pancreas is an important mechanism (Abigail
- 40 Fouden). Maternal hyperglycemia promotes fetal hyperinsulinemia (Pedersen's
- hypothesis)⁴⁸, lipids and amino acids probably work similarly (Freinkel's fuel mediated 41

teratogenesis)⁴⁹. In our novel approach we have investigated the possible involvement of 1 2 maternal ADsEV miRNAs in influencing fetal adiposity and suggest that DE ADsEV miRNAs in 3 both the maternal and neonatal circulation could influence neonatal adiposity through 4 regulating various cellular signaling pathways which are well-known to be involved in 5 different aspects of adipogenesis. Though our investigation does not allow us to confirm 6 maternal origin of ADsEVs in fetal circulation, many studies have demonstrated maternal-

7 fetal transfer of EVs.

8 Our study is perhaps the first of its kind to investigate association of maternal and

9 fetal ADsEV miRNAs and neonatal adiposity. This is a novel approach to fetal growth and

10 development and may provide useful leads into possible molecular mechanisms of maternal

- 11 fetal communication. An additional strength is a reasonable number of mother-baby dyads
- 12 in each group in a population which is characterized by adipose newborns (thin-fat Indian
- 13 babies). One of the limitations is that the maternal ADsEV miRNAs were measured only at
- 14 the time of delivery and thus after neonatal adiposity is established; we will investigate
- 15 maternal ADsEVs in early pregnancy to expand our findings. It is also true that the current
- 16 design is not provide conclusive proof of transfer of maternal ADsEVs to fetal circulation,
- 17 and therefore our results are to be considered hypothesis generating and in need of further
- 18 proof by experiments like HLA typing and matching of ADsEVs to track their origin.
- Moreover, as Indians are reported to have lower BAT compared to Europeans and it will be 19
- 20 interesting to pursue adiposity trajectory and metabolic outcomes in these children in
- 21 relation to cord blood ADsEVs. External validity of our findings will come only from
- 22 additional studies in other populations.

23 In summary, we demonstrate differential expression of ADsEV miRNAs both in 24 maternal and neonatal circulation in pregnancies with adipose neonates. These miRNAs 25 targeted different aspects of adipose tissue function and adipogenesis, supporting a 26 possible role in fetal adipogenesis. Studies in other populations and in early pregnancy will 27 improve our understanding of maternal-fetal communication which influences fetal body

- 28 composition.
- 29

33

30 Data availability

31 The demographic, phenotypic and raw microarray data is available with the authors and can 32 be made available for a reasonable request following institutional clearances.

34 Funding

35 The work was supported by InDiaGDM grant of the Department of Biotechnology, New Delhi, 36 India (BT/IN/Denmark/02/CSY/2014) and National Institute of Health (NIH), the U.S 37 government (R21HD094127-01).

38

39 Acknowledgement

40 The authors thank Deepa Raut, Neelam Memane, Sayali Wadke and Rajashree Kamat for their

- 41 help in processing cord blood samples and laboratory assays. Madhura Deshmukh for help in
- 42 study coordination. Mrs. Pallavi Yajnik and Rasika Ladkat for administrative help. Dr. Leelavati 43 Narlikar for her guidance in data analysis. Dr. Satyajit Rath for his advice in writing t

- discussion. We also thank the co-investigators of the InDiaGDM study Dr. Giriraj Chandak, 1
- 2 Kalyanaraman Kumaran, Dr. Gundu Rao for their valuable contribution in conducting the 3 InDiaGDM study.
- 4

5 Author contributions

- 6 CSY designed the InDiaGDM study. CSY and HD contributed to managing the clinical cohort.
- 7 DB, RKK, BH, ES, MB contributed to exosome extraction and protocol standardization. SR
- 8 contributed to microRNA data generation. PSK, PT, MB, RKK, KA, MG contributed to the
- 9 data analysis. PSK, MB, CSY, RF contributed to the manuscript writing. CSY and RF
- 10 contributed to discussion and interpretation of the results. All authors read and approved
- 11 the manuscript.
- 12
- 13

1 References

- Williams, R. Hardin., & Larsen, P. Reed. (2003). Chapter 20. Endocrine Changes in
 Pregnancy, Williams textbook of endocrinology. Saunders.
- Hales, C. N., & Barker, D. J. P. (2013). Type 2 (non-insulin-dependent) diabetes
 mellitus: the thrifty phenotype hypothesis. 1992. International Journal of
 Epidemiology, 42(5), 1215–1222. doi: 10.1093/ije/dyt133
- Yajnik, C. S., & Deshmukh, U. S. (2008). Maternal nutrition, intrauterine programming
 and consequential risks in the offspring. Reviews in Endocrine & Metabolic Disorders,
 9(3), 203–211. doi: 10.1007/s11154-008-9087-z
- 10 4. Katre P, & Yajnik C. (2015). Pune Experience.
- Yajnik, C S, Fall, C. H. D., Coyaji, K. J., Hirve, S. S., Rao, S., Barker, D. J. P., Joglekar, C., &
 Kellingray, S. (2003). Neonatal anthropometry: the thin-fat Indian baby. The Pune
 Maternal Nutrition Study. International Journal of Obesity and Related Metabolic
 Disorders : Journal of the International Association for the Study of Obesity, 27(2),
 173–180. doi: 10.1038/sj.ijo.802219
- Yajnik, C S, Lubree, H. G., Rege, S. S., Naik, S. S., Deshpande, J. A., Deshpande, S. S.,
 Joglekar, C. v, & Yudkin, J. S. (2002). Adiposity and hyperinsulinemia in Indians are
 present at birth. The Journal of Clinical Endocrinology and Metabolism, 87(12), 5575–
 5580. doi: 10.1210/jc.2002-020434
- Yajnik, Chittaranjan S, & Yajnik, P. C. (2020). Fetal adiposity epidemic in the modern
 world: a thrifty phenotype aggravated by maternal obesity and diabetes. AJCN. doi:
 10.1093/ajcn/nqaa122
- D'Angelo, S., Yajnik, C. S., Kumaran, K., Joglekar, C., Lubree, H., Crozier, S. R., Godfrey,
 K. M., Robinson, S. M., Fall, C. H. D., Inskip, H. M., & SWS Study Group and the PMNS
 Study Group. (2015). Body size and body composition: a comparison of children in
 India and the UK through infancy and early childhood. Journal of Epidemiology and
 Community Health, 69(12), 1147–1153. doi: 10.1136/jech-2014-204998
- Bavdekar, A., Yajnik, C. S., Fall, C. H., Bapat, S., Pandit, A. N., Deshpande, V., Bhave, S.,
 Kellingray, S. D., & Joglekar, C. (1999). Insulin resistance syndrome in 8-year-old Indian
 children: small at birth, big at 8 years, or both? Diabetes, 48(12), 2422–2429. doi:
 10.2337/diabetes.48.12.2422
- 10. Yajnik, C S, Deshpande, S. S., Jackson, A. A., Refsum, H., Rao, S., Fisher, D. J., Bhat, D.
 S., Naik, S. S., Coyaji, K. J., Joglekar, C. v, Joshi, N., Lubree, H. G., Deshpande, V. U.,
 Rege, S. S., & Fall, C. H. D. (2008). Vitamin B12 and folate concentrations during
 pregnancy and insulin resistance in the offspring: the Pune Maternal Nutrition Study.
 Diabetologia, 51(1), 29–38. doi: 10.1007/s00125-007-0793-y
- 11. Kaspar, D., Hastreiter, S., Irmler, M. et al. Nutrition and its role in epigenetic
 inheritance of obesity and diabetes across generations. Mamm Genome 31, 119–133
 (2020). https://doi.org/10.1007/s00335-020-09839-z

- 12. Reichetzeder, C. (2021). Overweight and obesity in pregnancy: their impact on 1 2 epigenetics. European Journal of Clinical Nutrition, 75, 1710–1722. doi: 10.1038/s41430-021-00905-6 3
- 13. Wang, K., Li, W.-D., Zhang, C. K., Wang, Z., Glessner, J. T., Grant, S. F. A., Zhao, H., 4 5 Hakonarson, H., & Price, R. A. (2011). A genome-wide association study on obesity and obesity-related traits. PloS One, 6(4), e18939. doi: 10.1371/journal.pone.0018939 6
- 7 14. Czernek, L., & Düchler, M. (2020). Exosomes as Messengers Between Mother and 8 Fetus in Pregnancy. International Journal of Molecular Sciences, 21(12). doi: 9 10.3390/ijms21124264
- 15. Sarker, S., Scholz-Romero, K., Perez, A., Illanes, S. E., Mitchell, M. D., Rice, G. E., & 10 11 Salomon, C. (2014). Placenta-derived exosomes continuously increase in maternal 12 circulation over the first trimester of pregnancy. Journal of Translational Medicine, 12, 13 204. doi: 10.1186/1479-5876-12-204
- 14 16. Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, 15 R., Antoniou, A., Arab, T., Archer, F., Atkin-Smith, G. K., Ayre, D. C., Bach, J.-M., 16 Bachurski, D., Baharvand, H., Balaj, L., Baldacchino, S., Bauer, N. N., Baxter, A. A., 17 Bebawy, M., ... Zuba-Surma, E. K. (2018). Minimal information for studies of 18 extracellular vesicles 2018 (MISEV2018): a position statement of the International 19 Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of 20 Extracellular Vesicles, 7(1), 1535750. doi: 10.1080/20013078.2018.1535750
- 21 17. Thomou T, Mori MA, Dreyfuss JM, et al. Adipose-derived circulating miRNAs regulate 22 gene expression in other tissues. Nature 2017;542:450-5.
- 23 18. Boon RA, Vickers KC. Intercellular transport of microRNAs. Arterioscler Thromb Vasc 24 Biol 2013;33:186-92.
- 25 19. Ferrante SC, Nadler EP, Pillai DK, et al. Adipocyte-derived exosomal miRNAs: a novel 26 mechanism for obesity-related disease. Pediatric research 2015;77:447-54.
- 27 20. Hubal MJ, Nadler EP, Ferrante SC, et al. Circulating adipocyte-derived exosomal 28 MicroRNAs associated with decreased insulin resistance after gastric bypass. Obesity 29 (Silver Spring) 2017;25:102-10.
- 30 21. Hromadnikova I, Kotlabova K, Dvorakova L, Krofta L, Sirc J. Substantially Altered 31 Expression Profile of Diabetes/Cardiovascular/Cerebrovascular Disease Associated microRNAs in Children Descending from Pregnancy Complicated by Gestational 32 33 Diabetes Mellitus-One of Several Possible Reasons for an Increased Cardiovascular Risk. Cells 2020;9. 34
- 35 22. Xie Z, Wang X, Liu X, et al. Adipose-Derived Exosomes Exert Proatherogenic Effects by 36 Regulating Macrophage Foam Cell Formation and Polarization. J Am Heart Assoc 37 2018,7.
- 23. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity 38 39 is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808. 40

1	24. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the
2	development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-30.
3	25. Wagle S, Phatak S, Bhat D et al. Adiposity and Glucose Intolerance in Offspring of
4	Diabetic Mothers in India. medRxiv 2021.05.17.21257222; doi:
5	https://doi.org/10.1101/2021.05.17.21257222
6	26. International Association of Diabetes and Pregnancy Study Groups Recommendations
7	on the Diagnosis and Classification of Glucose intolerance in Pregnancy. Diabetes Care.
8	2010;33(3):676-682.
9	27. Licursi, V., Conte, F., Fiscon, G. et al. MIENTURNET: an interactive web tool for
10	microRNA-target enrichment and network-based analysis. BMC Bioinformatics 20,
11	545 (2019). <u>https://doi.org/10.1186/s12859-019-3105-x</u>
12	28. Butts C (2015)network: Classes for Relational Data The Statnet Project
13	(<url:http: www.statnet.org="">). R package version 1.13.0.1, <url:https: cran.r-<="" td=""></url:https:></url:http:>
14	project.org/package=network>.
15	29. Wickham H (2016). ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New
16	York. ISBN 978-3-319-24277-4, <u>https://ggplot2.tidyverse.org</u> .
17	30. SankeyMATIC: A Sankey diagram builder for everyone (<u>https://sankeymatic.com/</u>)
18	31. Philippe Bardou, Jérôme Mariette, Frédéric Escudié, Christophe Djemiel and
19	Christophe Klopp. jvenn: an interactive Venn diagram viewer. BMC Bioinformatics
20	2014, 15:293 doi:10.1186/1471-2105-15-293
21	32. Ferland-McCollough, D., Fernandez-Twinn, D. S., Cannell, I. G., David, H., Warner, M.,
22	Vaag, A. A., Bork-Jensen, J., Brøns, C., Gant, T. W., Willis, A. E., Siddle, K., Bushell, M.,
23	& Ozanne, S. E. (2012). Programming of adipose tissue miR-483-3p and GDF-3
24	expression by maternal diet in type 2 diabetes. Cell Death and Differentiation, 19(6),
25	1003–1012. doi: 10.1038/cdd.2011.183
26	33. Nardelli, C., Iaffaldano, L., Pilone, V., Labruna, G., Ferrigno, M., Carlomagno, N.,
27	Dodaro, C. A., Forestieri, P., Buono, P., Salvatore, F., & Sacchetti, L. (2017). Changes in
28	the MicroRNA Profile Observed in the Subcutaneous Adipose Tissue of Obese Patients
29	after Laparoscopic Adjustable Gastric Banding. <i>Journal of Obesity, 2017,</i> 6754734. doi:
30	10.1155/2017/6754734
31	34. Joglekar, M. v, Kunte, P. S., Wong, W. K. M., Bhat, D. S., Satoor, S. N., Patil, R. R.,
32	Karandikar, M. S., Fall, C. H. D., Yajnik, C. S., & Hardikar, A. A. (2022). Circulating
33	microRNAs from early childhood and adolescence are associated with pre-diabetes at
34	18 years of age in women from the PMNS cohort. Journal of Developmental Origins of
35	Health and Disease, 1–6. doi: 10.1017/S2040174422000137
36	35. Wang, L., Xu, L., Xu, M., Liu, G., Xing, J., Sun, C., & Ding, H. (2015). Obesity-Associated
37	MiR-342-3p Promotes Adipogenesis of Mesenchymal Stem Cells by Suppressing CtBP2
38	and Releasing C/EBP α from CtBP2 Binding. Cellular Physiology and Biochemistry :
39	International Journal of Experimental Cellular Physiology, Biochemistry, and

All rights reserved. No reuse allowed without permission.

- 1 36. He, H., Chen, K., Wang, F., Zhao, L., Wan, X., Wang, L., & Mo, Z. (2015). miR-204-5p 2 promotes the adipogenic differentiation of human adipose-derived mesenchymal stem cells by modulating DVL3 expression and suppressing Wnt/ β -catenin signaling. 3 Molecular 4 International Journal of Medicine, 35(6), 1587-1595. doi: 5 10.3892/ijmm.2015.2160
- 37. Li, G., Fu, S., Chen, Y., Jin, W., Zhai, B., Li, Y., Sun, G., Han, R., Wang, Y., Tian, Y., Li, H.,
 & Kang, X. (2019). MicroRNA-15a Regulates the Differentiation of Intramuscular
 Preadipocytes by Targeting ACAA1, ACOX1 and SCP2 in Chickens. *International Journal*of Molecular Sciences, 20(16). doi: 10.3390/ijms20164063
- 38. Chen, Y., Buyel, J. J., Hanssen, M. J. W., Siegel, F., Pan, R., Naumann, J., Schell, M., van der Lans, A., Schlein, C., Froehlich, H., Heeren, J., Virtanen, K. A., van Marken Lichtenbelt, W., & Pfeifer, A. (2016). Exosomal microRNA miR-92a concentration in serum reflects human brown fat activity. *Nature Communications*, 7, 11420. doi: 10.1038/ncomms11420
- 39. Machado SA, Pasquarelli-do-Nascimento G, da Silva DS, Farias GR, de Oliveira Santos
 I, Baptista LB, Magalhães KG. Browning of the white adipose tissue regulation: new
 insights into nutritional and metabolic relevance in health and diseases. Nutr Metab
 (Lond). 2022 Sep 6;19(1):61. doi: 10.1186/s12986-022-00694-0. PMID: 36068578;
 PMCID: PMC9446768.
- 40. Zhu, Z., Cao, F., & Li, X. (2019). Epigenetic Programming and Fetal Metabolic
 Programming. Frontiers in Endocrinology, 10, 764. doi: 10.3389/fendo.2019.00764
- 41. Sebo, Z. L., Jeffery, E., Holtrup, B., & Rodeheffer, M. S. (2018). A mesodermal fate map
 for adipose tissue. Development (Cambridge, England), 145(17).
 doi:10.1242/dev.166801
- 42. Ambele, M. A., Dhanraj, P., Giles, R., & Pepper, M. S. (2020). Adipogenesis: A Complex
 Interplay of Multiple Molecular Determinants and Pathways. *International Journal of Molecular Sciences*, *21*(12). doi: 10.3390/ijms21124283
- 43. Ghaben, A. L., & Scherer, P. E. (2019). Adipogenesis and metabolic health. *Nature Reviews. Molecular Cell Biology*, 20(4), 242–258. doi: 10.1038/s41580-018-0093-z
- 44. Samblas, M., Milagro, F. I., & Martínez, A. (2019). DNA methylation markers in obesity,
 metabolic syndrome, and weight loss. *Epigenetics*, 14(5), 421–444. doi:
 10.1080/15592294.2019.1595297
- 45. Crocker, K. C., Domingo-Relloso, A., Haack, K., Fretts, A. M., Tang, W.-Y., Herreros, M.,
 Tellez-Plaza, M., Daniele Fallin, M., Cole, S. A., & Navas-Acien, A. (2020). DNA
 methylation and adiposity phenotypes: an epigenome-wide association study among
 adults in the Strong Heart Study. *International Journal of Obesity (2005), 44*(11), 2313–
 2322. doi: 10.1038/s41366-020-0646-z
- 46. Rosen, E. D., & MacDougald, O. A. (2006). Adipocyte differentiation from the inside
 out. *Nature Reviews. Molecular Cell Biology*, 7(12), 885–896. doi: 10.1038/nrm2066

47. Yajnik, C. S. (2014). Transmission of obesity-adiposity and related disorders from the mother to the baby. Annals of Nutrition & Metabolism, 64 Suppl 1, 8-17. doi: 10.1159/000362608 48. Pedersen J. Diabetes and pregnancy: Blood sugar of newborn infants (Ph.D. Thesis) Danish Science Press; Copenhagen: 1952. p. 230. 49. Freinkel N. Banting Lecture 1980. Of pregnancy and progeny. Diabetes 29(12): 1023-1035.

Table 1. Comparison of demographic characteristics between mothers of lean vs. mothers 1

2 of adipose neonates, and lean vs. adipose neonates

		Mothers of Lean		Mothers of Adipose	
	n	neonates	n	neonates	p-value
Age (yr)		26.9 (4.3)	75	27.9 (4.6)	0.234
Pre-pregnancy weight (kg)	47	54.0 (47.0, 62.0)	76	59.0 (50.8, 65.2)	0.076
Height (cm)	51	154.8 (6.0)	75	154.9 (5.4)	0.868
Weight (kg)	51	61.3 (54.7, 68.2)	75	66.7 (59.0, 75.6)	0.006
BMI (kg/m2)	51	25.0 (23.2, 27.6)	75	28.1 (25.4, 30.8)	0.003
Subscapular skin folds (mm)	50	34.7 (28.3, 41.3)	75	40.0 (29.0, 48.0)	0.058
% Adipose mothers		19/51 (37.2%)		42/76 (55.20%)	0.070
Fasting glucose (mg/dL)	51	80.0 (73.5, 87.0)	71	83.0 (78.0, 92.0)	0.034
% GDM mothers		17/51 (33.33%)		42/76 (55.26%)	0.024
Fasting Insulin (IU/L)	49	8.8 (5.9, 12.1)	68	9.7 (7.0, 14.5)	0.172
iHoma Sensitivity	49	106.6 (77.9, 152.3)	68	96.8 (63.3, 130.9)	0.133
iHoma Beta	49	125.7 (95.6, 144.6)	68	116.8 (93.7, 150.9)	0.932
iDI (*10 ³)	49	12.6 (10.4, 15.7)	68	11.2 (8.3, 14.7)	0.041
Vitamin B12 (pmol/L)	51	223 (171, 279)	73	206 (158, 280)	0.539
Folate (nmol/L)		57.4 (35.2, 70.7)	75	53.9 (25.3, 71.6)	0.612
Homocysteine (µmol/L)	29	6.8 (4.5, 7.5)	40	6.8 (5.8, 7.9)	0.496
Cholesterol (mg/dL)	49	203.7 (40.2)	71	193. (41.7)	0.179
Triglycerides (mg/dL)		144.0 (115.0, 213.0)	71	144.0 (115.5, 195.5)	0.949
HDL (mg/dL)		59.5 (14.1)	71	55.8 (13.3)	0.143
Neonatal characteristics (male=61, female=66)					
Gestational age (days)	51	229 (219, 244)	75	224 (211, 246)	0.607
Birth weight (g)	51	2519.3 (365.7)	76	3037.4 (369.1)	< 0.01
Birth Length (cm)	51	48.0 (46.2, 48.8)	76	49.0 (47.9, 49.7)	< 0.01
Sub-scapular skin fold (mm)	51	3.3 (3.0, 3.6)	76	5.2 (4.7, 5.8)	< 0.01
Placental weight (g)	51	360 (320, 405)	75	448 (390, 536)	< 0.01
Cord blood: Glucose (mg%)	51	60.0 (45.5, 80.5)	76	67.5 (52.8, 86.0)	0.379
Cord blood: Insulin (IU/L)	51	5.2 (2.2, 7.4)	76	6.9 (3.9, 12.5)	0.012
Cord blood: Vit B12 (pmol/L)	51	329 (199, 607)	76	288 (187, 475)	0.221
Cord blood: Folate (nmol/L)	51	57.4 (38.5, 69.2)	75	53.6 (33.5, 65.2)	0.214
Cord blood: Homocysteine					
(µmol/L)	41	6.4 (5.6, 8.9)	63	6.0 (5.0, 8.3)	0.133
Cord blood: Cholesterol (mg/dL)	51	53.0 (41.5, 62.5)	76	51.5 (40.0, 63.0)	0.996
Cord blood: Triglycerides			76		
(mg/dL)	51	46.0 (31.5, 52.5)	76	33.0 (25.0, 45.0)	< 0.01
Cord blood: HDL (mg/dL)	51	20 (15, 26)	76	21 (15, 27)	0.465

Note: Data are presented as mean (SD) and p-values are calculated by Student's T-test if 3

data is normally distributed, whereas median (25th, 75th centile) and p-values calculated by 4

5 Mann-Whitney are presented if data is not normally distributed.

Numbers and percentage are shown for % adipose mothers and % GDM mothers, p-values 6

7 are calculated by Chi-squared test.

8 BMI: Body Mass Index; HOMA: Homeostatic Model Assessment models, DI: Disposition

9 index. SD: Standard deviation.

1 Table 2A. Lists of differentially expressed ADsEV miRNAs in mothers of adipose Vs lean

2 neonates

Maternal miRNA (unadjus	sted)		Maternal miRNA (adjusted)		
					Fold
miRNA	P-value	Fold change	miRNA	P-value	change
hsa-miR-1202	0.061	1.544	hsa-miR-211-3p	0.073	1.55
hsa-miR-1234-3p	0.088	0.214	hsa-miR-212-3p	0.06	0.28
hsa-miR-1260a	0.057	1.784	hsa-miR-2276-3p	0.015	0.65
hsa-miR-212-3p	0.033	0.282	hsa-miR-3620-5p	0.053	-0.22
hsa-miR-3162-5p	0.082	0.911	hsa-miR-3928-5p	0.008	-0.09
hsa-miR-33b-3p	0.053	1.13	hsa-miR-4649-3p	0.013	0.45
hsa-miR-3656	0.097	1.744	hsa-miR-4655-5p	0.005	-1.58
hsa-miR-3928-5p	0.04	-0.085	hsa-miR-4695-3p	0.005	2.33
hsa-miR-3960	0.084	3.018	hsa-miR-4788	0.069	1.7
hsa-miR-4271	0.07	2.006	hsa-miR-483-3p	0.016	3.99
hsa-miR-4281	0.088	2.84	hsa-miR-6069	0.011	-0.07
hsa-miR-4512	0.065	-1.302	hsa-miR-6085	0.041	1.96
hsa-miR-451a	0.099	40.596	hsa-miR-6165	0.088	0.37
hsa-miR-4740-3p	0.047	2.488	hsa-miR-6511a-3p	0.014	0.33
hsa-miR-5739	0.097	1.622	hsa-miR-6743-5p	0.057	0.92
hsa-miR-5787	0.094	2.814	hsa-miR-6812-5p	0.032	-0.29
hsa-miR-6090	0.051	1.198	hsa-miR-6825-3p	0.024	-0.26
hsa-miR-6165	0.011	0.372	hsa-miR-8089	0.039	0.91
hsa-miR-6741-5p	0.018	1.083	hsa-miR-937-5p	0.1	0.95
hsa-miR-6749-5p	0.066	1.547			
hsa-miR-6803-5p	0.072	1.743]		
hsa-miR-6825-3p	0.082	-0.257			
hsa-miR-6869-5p	0.038	0.769			
hsa-miR-7977	0.057	2.809	1		

3

5 miRNAs in the unadjusted analysis and 19 miRNAs in adjusted analysis (adjusted for

6 maternal glycemic status (GDM/NGT), maternal adiposity (lean if below median and adipose

7 if above median), and maternal vitamin B12 and folate status (inadequate if below median

8 and adequate if above median)) were found to be differentially expressed at p<0.1.

9

Note: Lists of differentially expressed miRNAs in mothers of lean vs. adipose neonates; 24 4

1 Table 2B. Lists of differentially expressed ADsEV miRNAs in cord blood of adipose Vs lean

2 neonates

Cord miRNA (unadjus	ted)		Cord miRNA (adjusted)			
miRNA	P-value	Fold change	miRNA	P-value	Fold change	
hsa-miR-15a-5p	0.074	-0.912	has-let-7d-3p	0.091	9	
hsa-miR-3162-3p	0.087	1.49	hsa-miR-1225-5p	0.094	22.84	
hsa-miR-342-3p	0.049	-0.098	hsa-miR-1227-5p	0.02	1.43	
hsa-miR-4433a-5p	0.088	1.768	hsa-miR-1249-3p	0.061	1.27	
hsa-miR-483-5p	0.061	2.943	hsa-miR-1268a	0.077	2.52	
			hsa-miR-181b-5p	0.031	0.71	
			hsa-miR-204-5p	0.085	9.87	
			hsa-miR-212-3p	0.094	-0.39	
			hsa-miR-3162-3p	0.051	1.49	
			hsa-miR-320c	0.066	-5.12	
			hsa-miR-4433a-5p	0.02	1.77	
			hsa-miR-4634	0.087	-0.83	
			hsa-miR-4721	0.005	1.09	
			hsa-miR-4741	0.064	-7.01	
			hsa-miR-4788	0.069	-2.04	
			hsa-miR-519e-3p	0.077	7.03	
			hsa-miR-6089	0.078	4.37	
			hsa-miR-6124	0.092	9.77	
			hsa-miR-642b-3p	0.094	1.81	
			hsa-miR-6716-3p	0.019	7.8	
			hsa-miR-6815-3p	0.032	1.46	
			hsa-miR-6865-3p	0.054	2.02	
			hsa-miR-6866-3p	0.069	6.59	
			hsa-miR-8071	0.009	-0.94	
			hsa-miR-8089	0.037	0.29	
			hsa-miR-92a-3p	0.06	-0.36	

3

4 Note: Lists of differentially expressed miRNAs in cord blood of lean vs. adipose neonates; 5

5 miRNAs in the unadjusted analysis and 26 miRNAs in adjusted analysis (adjusted for

6 neonatal gender, maternal glycemic status (GDM/NGT), maternal adiposity (lean if below

7 median and adipose if above median), and maternal vitamin B12 and folate status

8 (inadequate if below median and adequate if above median)) were found to be differentially

9 expressed at p<0.1.

10

1 Figure legends:

- 2 Figure 1. Differentially expressed miRNAs between lean Vs adipose groups in maternal
- 3 and cord blood samples. Volcano plots of maternal (A, B) and cord blood (C, D) miRNAs.
- 4 Significantly upregulated are shown in blue and downregulated in red, non-significant in
- 5 green. A fold change cut off ±1.25 and a p-value cut-off of 0.1 are shown. Adjustment
- 6 included maternal GDM, adiposity, vitamin B12 and folate status, and additionally for
- 7 neonatal gender in cord blood.
- 8

9 Figure 2A. Differentially expressed ADsEV miRNAs highlighted in maternal unadjusted

- 10 analysis: The bar diagram (A) shows the DE miRNAs and their fold change expression in the
- 11 mothers of adipose neonates (unadjusted analysis) compared to mothers of lean neonates.
- 12 Fold change values have been capped to ± 5. The network plot (B) highlights functionally
- 13 enriched miRNAs from this analysis and their target genes. The bubble plot (C) reveals
- 14 different adipogenesis related pathways targeted by the functionally enriched miRNAs.
- 15

16 Figure 2B. Differentially expressed ADsEV miRNAs highlighted in maternal adjusted

- 17 **analysis**: The bar diagram (A) shows the DE miRNAs and their fold change expression in the
- 18 mothers of adipose neonates compared to mothers of lean neonates (adjusted analysis;
- 19 adjustments included maternal GDM, adiposity, vitamin B12 and folate status). Fold change
- 20 values have been capped to ± 5. The network plot (B) highlights functionally enriched
- 21 miRNAs from this analysis and their target genes. The bubble plot (C) reveals different
- 22 adipogenesis related pathways targeted by the functionally enriched miRNAs.
- 23

24 Figure 3A: Differentially expressed ADsEV miRNAs highlighted in cord blood unadjusted

- 25 analysis: The bar diagram (A) shows the DE miRNAs and their fold change expression in the
- 26 cord blood of adipose neonates (unadjusted analysis) compared to lean neonates. Fold
- 27 change values have been capped to ± 5. The network plot (B) highlights functionally
- 28 enriched miRNAs from this analysis and their target genes. The bubble plot (C) reveals
- 29 different adipogenesis-related pathways targeted by the functionally enriched miRNAs.
- 30

31 Figure 3B: Differentially expressed ADsEV miRNAs highlighted in cord blood adjusted

- 32 **analysis:** The bar diagram (A) shows the DE miRNAs and their fold change expression in the
- 33 cord blood of adipose neonates compared to lean neonates (adjusted analysis; adjustments
- 34 included maternal GDM, adiposity, vitamin B12 and folate status, and additionally for
- 35 neonatal gender in cord blood). Fold change values have been capped to \pm 5. The network
- 36 plot (B) highlights functionally enriched miRNAs from this analysis and their target genes.
- 37 The bubble plot (C) reveals different adipogenesis-related pathways targeted by the
- 38 functionally enriched miRNAs.
- 39

1	Figure 4: Complex interplay of DE ADsEVs miRNAs from maternal and cord blood in
2	adipogenesis related pathways
3	The Sankey diagram shows the DE miRNAs in maternal and cord blood of adipose neonates
4	and their targeted pathways related to adipogenesis. The diagram highlights that though the
5	differentially expressed miRNAs were different in maternal and cord blood, they targeted
6	similar adipogenesis-related pathways. The numbers represent the total number of targeted
7	genes.
8	
9	Figure 5: Comparison of differentially expressed miRNAs in the 3 analyses: The Venn
10	diagram shows the number of differentially expressed miRNAs found common and exclusive
11	to following 3 independent comparisons: 1, Neonatal adiposity (Lean Vs Adipose), 2.
12	Maternal hyperglycemia during pregnancy (NGT Vs GDM), and 3. Maternal adiposity (Lean
13	vs. Adipose)
14	
15	Supplementary figure 1: STROBE flow diagram for the selection of participants
16	
17	Supplementary figure 2: STROBE Flow diagram for miRNA analysis
18	
19	Supplementary figure 3: Comparison of average z-score of miRNA expression profile in
20	maternal and cord blood samples between lean Vs adipose groups: The boxplots highlight
21	that (A) the average z-score of all miRNA expression was lower in mothers of adipose
22	neonates (red color) as compared to mothers of lean neonates (green color) (p=0.053). This
23	pattern was not observed in the cord blood (B) of adipose and lean neonates (p=0.645). The
24	z-scores were calculated as per the formula:
25	Z-score = average (expression of miRNA in each sample - median expression of that miRNA)/
26	Std. dev(miRNA))
27	

Figure 1. Differentially expressed miRNAs between lean Vs adipose groups in maternal and cord blood samples.

Group e Down e NS e Up



Figure 2A



hsa.miR.3162.5p

hsa.miR.212.3p

hsa.miR.1260a

hsa.miR.1234.3p

hsa.miR.1202

1 2 3 4

Fold change

5

-1 0

SOX11

TWIST1

HMGA2

RFXAP

CCNA2

CCNB1

ABCG2

RBP2

PTCH1

SOX4

C: Pathways



Figure 2B





Figure 3A

Pathways

C: Pathways





Figure 3B

C: Pathways



miRNA in Cord Blood (adj.)

medRxiv preprint doi: https://doi.org/10.1101/2022.10.30.22281708; this version posted November 1, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

Figure 4. Complex interplay of DE ADsEVs miRNAs from maternal and cord blood in adipogenesis related pathways





Maternal

Figure 5. Comparison of differentially expressed miRNAs in the 3 analyses

Neonatal







Maternal



Total miRNAs

Adipogenesis related miRNAs